Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anastasia Rays
Observed names:
A. B. Rays,
A. Rays,
Anastasia B. Rays,
Anastasia Rice,
А. Б. Райс
Institutions:
Russian Cancer Research Center NN Blokhin,
Moscow Multidisciplinary Clinical Center "Kommunarka"
Observed institutions:
Russian Cancer Research Center NN Blokhin,
Ministry of Health of the Russian Federation,
Moscow Multidisciplinary Clinical Center "Kommunarka"
ORCID:
0000-0001-5219-2890
Observed ORCID:
0000-0001-5219-2890
OpenAlex ID:
A5049657379
Meta-analysis of studies on the effectiveness of adding anti-PD1 antibodies to the first-line chemotherapy in advanced esophageal cancer
2023
·
M. Yu. Fedyanin
, A. A. Tryakin
, et al.
·
Malignant tumours
·
6
PDF
Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study
2024
·
A. B. Rays
, М. Yu. Fedyanin
, et al.
·
Malignant tumours
·
3
PDF
Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
2025
·
Anastasia Rays
, Мikhail Fedyanin
, et al.
·
Exploration of Digestive Diseases
·
2
P-224 Тoxicity and tolerability of the mFOLFIRINOX regimen in young elderly and older elderly patients with pancreatic carcinoma (PC)
2022
·
M. Manukyan
, I. Bazin
, et al.
·
Annals of Oncology
·
2
Analysis of the efficacy and safety of regorafenib versus chemotherapy retreatment in 3rd line treatment of metastatic colorectal cancer
2026
·
Grigoriy M. Naydin
, D. А. Barsova
, et al.
·
Surgery and Oncology
·
1
PDF
Prognostic and predictive factors in patients with metastatic gastric cancer treated with immune checkpoint inhibitors
2024
·
A. B. Rays
, M. Yu. Fedyanin
, et al.
·
Surgery and Oncology
·
1
Addition of anti-PD1 antibodies to chemotherapy (CT) in first-line treatment of advanced esophageal cancer (EC): A systematic review and meta-analysis.
2022
·
Anastasia Rice
, Mikhail Fedyanin
, et al.
·
Journal of Clinical Oncology
·
1
Prognostic significance of KRAS, NRAS, and BRAF mutations in patients with colorectal cancer and liver metastases: results of a single-center retrospective study
2026
·
Georgii G. Makiev
, Mikhail Yu. Fedyanin
, et al.
·
Russian Journal of Biotherapy
95P Comparative performance of prognostic models in resectable colorectal liver metastases: A single-center retrospective study
2026
·
G.G. Makiev
, E. Timofeeva
, et al.
·
Annals of Oncology
PDF
98P Comparison of three-component and two-component chemotherapy regimens in patients with isolated unresectable and potentially resectable colorectal cancer liver metastases: Results of a retrospective study
2026
·
G.G. Makiev
, R.S. Abdulaeva
, et al.
·
Annals of Oncology
PDF
Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer
2026
·
G. M. Naydin
, G. G. Makeev
, et al.
·
Malignant tumours
PDF
Efficacy of chemoimmunotherapy in first-line treatment of patients with disseminated gastric cancer depending on PD-L1 expression and clinical benefit according to the ESMO-MCBS and RUSSCO criteria: results of a meta-analysis
2026
·
M. Yu. Fedyanin
, A. B. Rays
, et al.
·
Malignant tumours
PDF
Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation.
2026
·
Mikhail Fedyanin
, Evgenia Kuzmina
, et al.
·
Journal of Clinical Oncology
PDF
Multicenter, nonrandomized clinical trial to evaluate the efficacy and toxicity of a combination of targeted therapy and chemotherapy in the second-line treatment of patients with metastatic inoperable colorectal cancer.
2026
·
Mikhail Fedyanin
, Evgenia Kuzmina
, et al.
·
Journal of Clinical Oncology
PDF
460eP Real-world outcomes of patients with advanced hepatocellular carcinoma: A retrospective cohort study
2025
·
A. Rays
, E. Kotova
, et al.
·
Annals of Oncology
238eP Comparison of the efficacy of regorafenib and reintroduction of chemotherapy (CT) with anti-EGFR in the 3rd-line treatment of metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF of left-sided localization - results of a retrospective study
2025
·
E. Kuzmina
, P. Feoktistova
, et al.
·
Annals of Oncology
Предварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом
2025
·
Е. С. Кузьмина
, М. Ю. Федянин
, et al.
·
Malignant tumours
PDF
74eP Impact of rare KRAS mutations on resectability, conversion, and survival in patients with colorectal cancer liver metastases: A retrospective single-center study
2025
·
G.G. Makiev
, M. Fedyanin
, et al.
·
ESMO Open
PDF
WITHDRAWN: 2835P Desensitization success in patients with chemotherapy-related hypersensitivity reactions: The impact of premedication and infusion protocol - Moscow Multidisciplinary Clinical Center "Kommunarka" experience
2025
·
E. Glazkova
, D.A. Ivanilova
, et al.
·
Annals of Oncology
9P Total neoadjuvant therapy with trastuzumab in HER2-positive gastric and gastroesophageal junction adenocarcinoma: Interim analysis results
2025
·
R.S. Abdulaeva
, L.R. Shulumba
, et al.
·
ESMO Open
PDF
136eP Resectability of colorectal liver metastases according to RAS and BRAF-mutational status: A single-center retrospective study
2025
·
G.G. Makiev
, M. Fedyanin
, et al.
·
ESMO Open
Efficacy of immunochemotherapy (ICT) in patients (pts) with metastatic gastric cancer (mGC) in context of ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and PD-L1 expression: Results of the meta-analysis.
2025
·
Mikhail Fedyanin
, Alexey Tryakin
, et al.
·
Journal of Clinical Oncology
PDF
Interim results of a prospective randomised single-centre phase III study comparing mFOLFIRINOX and mFOLFOX6 regimens in the first-line treatment of HER2-negative gastric adenocarcinoma
2024
·
D. A. Gavrilova
, N. S. Besova
, et al.
·
Medical alphabet
PDF
Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC.
2024
·
Darya Kravchuk
, Mikhail Fedyanin
, et al.
·
Journal of Clinical Oncology
PDF
“Interchangeability” of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM).
2023
·
Darya Kravchuk
, Mikhail Fedyanin
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
26
Citation count:
16
H-index:
2
I10-index:
Year
Topic
Type